The NPM1 mutation, typically a favorable prognostic marker in newly diagnosed AML, loses this advantage in the relapsed/refractory setting. Survival for relapsed NPM1 patients becomes as poor as for those without the mutation, justifying aggressive targeted therapy with menin inhibitors.

Despite impressive data supporting HMA/Venetoclax, its application in younger, fit patients must be cautious. The pivotal VIALE-A trial excluded key subgroups like FLT3, core binding factor, and certain NPM1 patients, for whom intensive chemotherapy remains the standard.

Despite clinical efficacy, menin inhibitor monotherapy provides a relatively short duration of response (4-6 months) in the relapsed/refractory setting. Their main clinical benefit is achieving a deep enough remission to allow patients to proceed to a potentially curative allogeneic stem cell transplant.

The IDH1 inhibitor olutasidenib demonstrates a much longer duration of response than ivosidenib. One hypothesis is that olutasidenib's weaker affinity for wild-type IDH1 makes it a more selective inhibitor of the mutant protein, leading to more durable disease control.

The development of agents targeting specific mutations like CALR and JAK2V617F marks a move away from the "one size fits all" JAK inhibitor approach. This enables a more personalized, molecularly-driven treatment strategy that was previously not possible for MPN patients.

While quizartinib's benefit is less pronounced in AML patients over 60, a specific genomic signature—the co-occurrence of FLT3-ITD, NPM1, and DNMT3A mutations—identifies a subset of older patients who derive a significant survival benefit, challenging age-based treatment decisions.

Post-transplant maintenance strategy differs by mutation. For high-risk KMT2A-rearranged AML with less sensitive monitoring, maintenance is strongly considered. For NPM1-mutated AML, clinicians rely on highly sensitive qPCR for Minimal Residual Disease (MRD); if a patient is MRD-negative, they often forgo maintenance therapy.

The Spanish KIWI trial showed a surprising survival benefit for quizartinib in FLT3-ITD negative AML. The benefit was greatest in patients with NPM1 and DNMT3A mutations, suggesting the drug's efficacy extends beyond its primary target through other mechanisms.

A key advantage of the FLT3 inhibitor quizartinib over midostaurin is its demonstrated survival benefit in FLT3-ITD positive AML patients who do not proceed to an allogeneic transplant in their first remission. This makes it a more robust upfront option for a broader patient group.